The Spanish Ministry of Science and Innovation recently published the final award resolution of aid for Projects in Strategic Lines.
These projects are intended to support industrial research projects carried out in cooperation between companies and R&D agents, both public and private, in order to respond to the challenges identified in the thematic priorities topics.
24 out of the 61 approved projects (36% of total) are classified as "biotech." ZeClinics is one of the 17 Asebio partners (including 9 companies and 7 entities) that have benefited from these public resources in the current call.
Biotech numbers in the 17 thematic priorities:
For the priority Development of new alternative methods to reduce animal experimentation, 10 projects have been awarded, representing 15% of the total. These projects have received a total of 4.3 million euros (12%) in the form of a grant and 1.4 million euros (10%) in the form of a loan.
For the priority New approaches to understand the mechanisms and establish new strategies for solid tumor cancer immunotherapy, 8 projects have been awarded, representing 12% of the total. These projects have received a total of 5.2 million euros (15%) in the form of a grant and 3.9 million euros (26%) in the form of a loan.
For the priority Safe physical methods for the diagnosis and treatment of diseases, a total of 7 projects have been awarded, representing 10%. These projects have received a total of 4.4 million euros (12.4%) in the form of a grant and 1.3 million euros (9.3%) in the form of a loan.
View full article